Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.

Scientific reports - 11 May 2017

Lee Ju-Han, Jeong Hoiseon, Choi Jung-Woo, Oh HwaEun, Kim Young-Sik

Abstract excerpt

The precise clinicopathologic significance of myeloid differentiation primary response gene (MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Codon
Share to Lymphoma, Large B-Cell, Diffuse

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation Rate

Share to Myeloid Differentiation Factor 88

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Publication Bias

Source

Open in PubMed Open full text

Identifiers

PMID: 28496180
DOI: 10.1038/s41598-017-01998-5
PMCID: PMC5431939

Genes

MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.PMID 28496180Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.Semantic proximity Read ↗

Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.Semantic proximity Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.Semantic proximity Read ↗

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.Semantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphomaSemantic proximity Read ↗

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.Semantic proximity Read ↗

MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.Semantic proximity Read ↗

Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.